Use este identificador para citar ou linkar para este item:
https://www.arca.fiocruz.br/handle/icict/38975
Tipo de documento
ArtigoDireito Autoral
Acesso restrito
Data de embargo
2100-01-01
Coleções
Metadata
Mostrar registro completo
DURATION OF POST-VACCINATION HUMORAL IMMUNITY AGAINST YELLOW FEVER IN CHILDREN
Immunogenicity
Vaccination policy
Duration of immunity in children
Autor(es)
Noronha, Tatiana Guimarães de
Maia, Maria de Lourdes de Sousa
Ribeiro, José Geraldo Leite
Lemos, Jandira Aparecida Campos
Lima, Sheila Maria Barbosa de
Martins Filho, Olindo Assis
Azevedo, Ana Carolina Campi
Freire, Marcos da Silva
Martins, Reinaldo de Menezes
Camacho, Luiz Antonio Bastos
Collaborative Group for Studies of Yellow Fever Vaccine
Maia, Maria de Lourdes de Sousa
Ribeiro, José Geraldo Leite
Lemos, Jandira Aparecida Campos
Lima, Sheila Maria Barbosa de
Martins Filho, Olindo Assis
Azevedo, Ana Carolina Campi
Freire, Marcos da Silva
Martins, Reinaldo de Menezes
Camacho, Luiz Antonio Bastos
Collaborative Group for Studies of Yellow Fever Vaccine
Afiliação
Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, RJ, Brasil.
Estado de Minas Gerais. Secretaria de Saúde. Belo Horizonte, MG, Brasil.
Estado de Minas Gerais. Secretaria de Saúde. Belo Horizonte, MG, Brasil.
Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brasil.
Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brasil.
Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Escola Nacional de Saúde Pública Sergio Arouca. Rio de Janeiro, RJ, Brasil.
The Collaborative Group for Studies of Yellow Fever Vaccine.
Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, RJ, Brasil.
Estado de Minas Gerais. Secretaria de Saúde. Belo Horizonte, MG, Brasil.
Estado de Minas Gerais. Secretaria de Saúde. Belo Horizonte, MG, Brasil.
Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brasil.
Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brasil.
Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Escola Nacional de Saúde Pública Sergio Arouca. Rio de Janeiro, RJ, Brasil.
The Collaborative Group for Studies of Yellow Fever Vaccine.
Resumo em Inglês
INTRODUCTION: Vaccination is the most important measure for prevention and control of yellow fever. It is recommended by the World Health Organization (WHO) for residents of endemic areas and travelers to risk areas. In 2013, the WHO discontinued the recommendation of booster doses every 10 years, indicating a single dose as sufficient for lifelong protection. OBJECTIVE: Considering the lower immune response to YF vaccine in children compared to adults, this study was set out to assess the duration of immunity to YF in children vaccinated in the first two years of life.
METHODS: This cross-sectional study involved children aged 9 months to 12 years with accessible vaccination records recruited in primary care units from a metropolitan area in Southeast Brazil. The serologic status (negative, indeterminate and positive), and geometric mean titers (GMT, inverse dilution) of neutralizing antibodies against YF obtained by Plaque Reduction Neutralization Test was assessed across categories of time after YF vaccination. The strength of association of seropositivity with time was assessed by the odds ratio (OR) taking recent vaccination (1-6 months) as reference. RESULTS: A total of 824 children recruited from August 2010 to July 2011were tested. The proportion of seropositivity (95% C.I.) and GMT (95% C.I.) dropped markedly across time periods: from 86.7% (80.5-91.4%), GMT 47.9 (38.3-59.9) in newly vaccinated to 59.0% (49.7-67.8%), GMT 14.8 (11.6-19.1) and 42.2% (33.8-51.0), GMT 8.6 (7.1-12.1), respectively in the subgroups vaccinated 31-72 months and 73-100 months before. CONCLUSIONS: Analogous to previous findings in adults, these data support the need for revaccination of children living in areas with yellow fever virus circulation in humans or in other primates. The data also supported the change of a booster dose to 4 years of age for those primarily vaccinated for yellow fever in the first two years of life.
Palavras-chave em inglês
Yellow fever vaccineImmunogenicity
Vaccination policy
Duration of immunity in children
Compartilhar